Crestor - Astrazeneca
Crestor is the brand name drug sold by AstraZeneca of the drug rosuvastatin calcium. It is a lipid-lowering agent for oral administration.
Latest Date for Prior Art: 06/11/1991
The patent in this study is a reissue of US 5,260,444. The reissue application was filed on August 27, 1998, more than 2 years after the â€˜444 Patent issued. A reissue patent application filed more than 2 years after issuance can only seek to narrow the claims of the original patent. The only claims allowed in the reissue application were claims 6, 7 and 8. Therefore Re37,314 only covers the specific compound of claim 6 and the sodium or calcium salts thereof.
During the prosecution of the reissue application, the applicant successfully argued that the chemical composition shown in claim 6 was not anticipated or obvious. A copy of the imaged filewrapper is available on the USPTO website. You can access the filewrapper by using the PAIR function at the USPTO site.
The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt.
All references need to have either been filed or published on or before this date. Any references filed or published after the LDPA will be automatically declined.
Specific claims or technical disclosures on which the scope of the Study is based. Your submissions should be based on these requirements.
- The Winner is guaranteed a minimum amount ($2,000 for a $4,500 Study). The Winner receives a $500 bonus for a winning NPL or Chinese/Japanese patent, and an additional $500 if the winning NPL is non-English.
- Two (2) CrowdSource Experts will receive $500 each.
- Up to five (5) MVRs will receive $100 each.